Article
Multidisciplinary Sciences
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van't Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Summary: HER2-targeted therapy significantly improves outcomes in early breast cancer patients. Two HER2-targeted combinations have shown promising efficacy in early breast cancer patients at high risk of recurrence, potentially aiding in identifying patients who can safely reduce cytotoxic chemotherapy without compromising outcomes.
NATURE COMMUNICATIONS
(2021)
Letter
Medicine, General & Internal
Sreeram V. Ramagopalan, Riccardo Pisoni, Lokendra Singh Rathore, Joshua Ray, Cormac Sammon
Summary: This cohort study compares the efficacy of combined pertuzumab, trastuzumab, and docetaxel therapy in women with metastatic breast cancer with the results of the CLEOPATRA trial.
Article
Oncology
Martine Piccart, Marion Procter, Debora Fumagalli, Evandro de Azambuja, Emma Clark, Michael S. Ewer, Eleonora Restuccia, Guy Jerusalem, Susan Dent, Linda Reaby, Herve Bonnefoi, Ian Krop, Tsang-Wu Liu, Tadeusz Pienkowski, Masakazu Toi, Nicholas Wilcken, Michael Andersson, Young-Hyuck Im, Ling Ming Tseng, Hans-Joachim Lueck, Marco Colleoni, Estefania Monturus, Mihaela Sicoe, Sebastien Guillaume, Jose Bines, Richard D. Gelber, Giuseppe Viale, Christoph Thomssen
Summary: The PURPOSEAPHINITY study demonstrates that adding pertuzumab to adjuvant therapy with trastuzumab and chemotherapy significantly improves invasive disease-free survival for early HER2-positive breast cancer patients. Longer follow-up is needed for a comprehensive assessment of overall survival benefits.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Stephanie Gu, Stephen Dusza, Elizabeth Quigley, Helen Haliasos, Alina Markova, Michael Marchetti, Andrea P. Moy, Chau Dang, Shanu Modi, Diana Lake, Sarah Noor, Mario E. Lacouture
Summary: This retrospective analysis examined the occurrence of pruritus in HER2 + breast cancer patients receiving trastuzumab and pertuzumab treatment. The results showed that pruritus was rare but could occur at different times after treatment initiation and mainly affected the upper extremities, back, lower extremities, and shoulders. Most cases of pruritus were grade 1/2, and patients responded well to treatment with topical steroids, antihistamines, emollients, and gabapentinoids. A small number of patients required treatment interruption or discontinuation.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Sheau Wen Lok, Richard De Boer, Sally Baron-Hay, Peter Button, Bianca Devitt, Benjamin C. Forster, Peter Fox, Michael Harold, Sahisha Ketheeswaran, Ganessan Kichenadasse, Belinda E. Kiely, Gavin Marx, Louise Nott, Laura Pellegrini, Ali Tafreshi, Peter Gibbs
Summary: This study analyzed the safety and effectiveness data of pertuzumab in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia. The results revealed that pertuzumab showed effectiveness in surgical outcomes and the safety data align with previous clinical trials, without any new safety concerns.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Thibaut Sanglier, Alessandra Fabi, Carlos Flores, Evelyn M. Flahavan, Claudia Pena-Murillo, Anne-Marie Meyer, Filippo Montemurro
Summary: Real-world studies suggest that trastuzumab emtansine (T-DM1) may be less effective in patients with metastatic breast cancer who have received prior pertuzumab treatment. However, these studies may have been biased towards selecting patients with more aggressive disease. Our study evaluated the impact of this selection bias and found that patients who entered the study earlier had poorer outcomes compared to those who entered more recently, indicating that selection bias should be considered in treatment assessments.
Article
Oncology
Chau Dang, Michael S. Ewer, Suzette Delaloge, Jean-Marc Ferrero, Ramon Colomer, Luis de la Cruz-Merino, Theresa L. Werner, Katherine Dadswell, Mark Verrill, Daniel Eiger, Sriparna Sarkar, Sanne Lysbet de Haas, Eleonora Restuccia, Sandra M. Swain
Summary: The BERENICE study assessed the cardiac safety of neoadjuvant-adjuvant therapy for high-risk, HER2-positive early breast cancer. The study confirmed that pertuzumab-trastuzumab-based therapies are the standard of care for this patient population, with no new cardiac issues reported.
Article
Immunology
Yi Xiao, Jiahan Ding, Dachang Ma, Sheng Chen, Xun Li, Keda Yu
Summary: This study found that the HER2/CEP17 ratio, CD8 levels, and histological grade were significantly correlated with pathological complete response (pCR) in dual-targeted neoadjuvant treatment. The combined model using these three markers provided a better predictive value for pCR than the individual markers alone, indicating that the immunological effect partially mediates the predictive impact of neoadjuvant treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Luai S. Al Rabadi, Madeline M. Cook, Andy J. Kaempf, Megan M. Saraceni, Michael A. Savin, Zahi Mitri
Summary: The study showed that prior exposure to pertuzumab did not significantly impact the clinical efficacy or safety profile of T-DM1 as second- or later-line therapy in patients with metastatic HER2-positive breast cancer.
Article
Oncology
Adrienne G. Waks, Neelam V. Desai, Tianyu Li, Philip D. Poorvu, Ann H. Partridge, Natalie Sinclair, Laura M. Spring, Meredith Faggen, Michael Constantine, Otto Metzger, Jillian Alberti, Julia Deane, Shoshana M. Rosenberg, Elizabeth Frank, Sara M. Tolaney, Ian E. Krop, Nadine M. Tung, Nabihah Tayob, Tari A. King, Elizabeth A. Mittendorf, Eric P. Winer
Summary: De-escalating adjuvant therapy in HER2+ breast cancer patients who achieve pCR is a feasible approach with high adherence rate to antibody-only therapy. Further prospective trials are needed to determine long-term efficacy.
Article
Oncology
Claudia Omarini, Federico Piacentini, Isabella Sperduti, Krisida Cerma, Monica Barbolini, Fabio Canino, Cecilia Nasso, Christel Isca, Federica Caggia, Massimo Dominici, Luca Moscetti
Summary: This study used a meta-analysis of real world data to investigate the efficacy of T-DM1 in HER2 positive MBC patients after first-line TP treatment. The results indicate that the efficacy of T-DM1 after TP appears to be similar to that reported in the EMILIA trial. However, more data is needed to confirm the efficacy of T-DM1 in the second-line setting.
Article
Pharmacology & Pharmacy
Minwoo Kang, Jong Il Shin, Sangjin Han, Jung Young Kim, Jeonghoon Park, Kwang Il Kim, Joo Hyun Kang, Tae Sup Lee
Summary: This study evaluated the feasibility of monitoring therapeutic response using Zr-89-DFO-pertuzumab immuno-PET imaging agent for HER2-targeted therapy. The results showed that Zr-89-DFO-pertuzumab can clearly visualize HER2 expressing tumors and demonstrated significant HER2 downregulation in 17-DMAG treated tumors.
Article
Medicine, General & Internal
Valentina Guarneri, Fara Braso-Maristany, Maria Vittoria Dieci, Gaia Griguolo, Laia Pare, Mercedes Marin-Aguilera, Federica Miglietta, Michele Bottosso, Carlo Alberto Giorgi, Paula Blasco, Oleguer Castillo, Patricia Galvan, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, PierFranco Conte, Aleix Prat
Summary: This study evaluated the predictive ability of HER2DX in early-stage HER2-positive/hormone receptor-positive breast cancer. The results showed that HER2DX scores were associated with the response to letrozole and dual HER2 blockade with trastuzumab and pertuzumab.
Article
Oncology
E. de Azambuja, E. Agostinetto, M. Procter, D. Eiger, N. Ponde, S. Guillaume, D. Parlier, M. Lambertini, A. Desmet, C. Caballero, C. Aguila, G. Jerusalem, J. M. Walshe, E. Frank, J. Bines, S. Loibl, M. Piccart-Gebhart, M. S. Ewer, S. Dent, C. Plummer, T. Suter
Summary: This study analyzed the cardiac safety of dual blockade with Pertuzumab and Trastuzumab in HER2-positive early breast cancer patients. The results showed that the use of Pertuzumab and Trastuzumab together did not increase the risk of cardiac events compared to Trastuzumab alone. Therefore, non-anthracycline chemotherapy may be considered in patients with cardiovascular risk factors.
Article
Oncology
Yutaka Yamamoto, Hiroji Iwata, Naruto Taira, Norikazu Masuda, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Tomomi Fujisawa, Naoki Niikura, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno
Summary: This study aimed to examine the efficacy of pertuzumab retreatment for HER2-positive locally advanced or metastatic breast cancer. The results showed that adding pertuzumab significantly improved progression-free survival in all patients and showed a trend towards better overall survival and duration of response.